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5Foreword
The conference Identifying Europe’s information needs for effective drug policy marked 
the 15th anniversary of the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA), and our activity of monitoring drugs and drug addiction in the European 
Union. It had several objectives: to better understand the current needs of policymakers, 
practitioners and researchers, to identify new developments in the drugs field and new 
results of drug-related research, and to provide input on the future work of the EMCDDA 
and its partners.
This publication summarises the presentations and discussions from the plenary and 
parallel sessions. It reflects the dynamism and commitment of those who study and 
respond to the drugs problem, and who made the conference such a productive, 
stimulating and successful event. The content of this publication will therefore be a vital 
tool for guiding the further development of our activities here in Lisbon.
The drugs problem Europe faces today is a far more complicated and dynamic 
phenomenon than it was when the EMCDDA came into existence. The challenge ahead of 
us is to keep pace with change and provide policymakers with an up-to-date 
understanding of the issues they face. The conference confirmed the need to ensure the 
effective monitoring of new substances and patterns of use, to assess their implications and 
to better feed this information into the policy debate. This is in line with the European drug 
strategy and action plan which are based on the premise that actions should be evidence 
driven and that we work most effectively when we work together.
The EMCDDA has always monitored certain aspects of drug supply (seizures, price and 
purity, drug law offences). However, further development is still needed, particularly in the 
area of supply reduction. A number of countries in Europe have already looked closely at 
supply reduction initiatives and strategies. A message from this conference is that such 
assessments should be more widespread and I recognise the need for the EMCDDA to work 
closely with our partners from Europol and the European Commission and the Reitox 
national focal points to improve the information tools and the analysis available in this area.
The world today is also a very different place than it was fifteen years ago. We have seen 
a revolution in information technologies which has had an impact on every aspect of 
modern life. The Internet, in particular, has brought both new opportunities and new 
challenges which will grow in importance in the coming years. We will therefore need to 
invest more in resources for monitoring developments in this area.
Fifteen years ago, European policymakers decided that there was a need for an 
independent information point on drugs. Today, Europe possesses considerable capacities 
to monitor the drugs problem and I strongly believe that this is one of the main reasons 
why our responses are better and more effective. Although it is clear that the EMCDDA 
played an important role in this process, we would not have made it without the work of 
the Reitox national focal points that have been the driving force behind much of the 
progress made. Let me thank them here for the remarkable job they do in providing data 
and information on Europe’s drug problem and for the contribution they made to the 
success of this conference.
Identifying Europe’s information needs for effective drug policy
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On a more personal note, I would also like to thank the President of the Portuguese 
Republic, Mr Aníbal Cavaco Silva and the Prime Minister, Mr José Sócrates, for their 
participation at the opening and closing sessions of the conference. I appreciate their 
taking the time to come and talk to the delegates and hence confirm the commitment of 
our host nation to the work of the EMCDDA. 
The overall conclusion from the conference confirmed my belief that we become stronger 
through exchanges and collective learning opportunities such as this. Europe is a 
formidable laboratory of ideas and experiences, and an amazing reservoir of people and 
talents. One of the key tasks of the EMCDDA is to bring these talents closer together and 
allow experience and knowledge to be shared. The conference clearly encouraged such 
exchanges and underlined the value of a European perspective.
Wolfgang Götz 
Director
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9Conclusions: what has the EMCDDA learnt?
Paul Griffiths and Roland Simon, EMCDDA 
The EMCDDA conference Identifying Europe’s information needs for effective drug policy 
marked 15 years of drugs monitoring history in the European Union but it was not an 
historical review. It showed us where we are today, and more importantly, where to go 
tomorrow.
This conference was staged at a key point in time, with the EMCDDA on the threshold of a 
new three-year work programme 2010–12. In the preparation of the conference we 
looked for speakers with a vision, and we will now identify findings that have direct 
relevance to our work, explore how we might take these results forward and take concrete 
steps to integrate them in our work.
During the conference we saw a large diversity of excellent presenters and presentations, 
we had great opportunities to meet, to network and to exchange ideas between all the 
different groups and stakeholders working with the EMCDDA who often might not meet: 
the Management Board, the Scientific Committee, the national focal points and other 
experts involved in the Reitox network, people working in the field, and not least EMCDDA 
staff, who appreciated the opportunity to listen, learn, and discuss.
The conference was built around four main themes: Policy, Practice, Trends and Horizons. 
We will look at them each in turn: what were the main findings, what was new, what was 
confirmed, what are the implications for our work.
The policy aspects discussed during the conference were manifold. Participants expressed 
a strong and growing commitment to evidence-driven policies, which is difficult to achieve 
as policies may have shifting priorities and there is no stable concept. Nevertheless, there 
is a growing interest in the evaluation of the effectiveness of existing or new drug policies 
and although science is not the only basis for political decisions, it is a crucial one as 
policymakers need a relevant knowledge base and options which allow them to take 
decisions. Despite the different perspectives that may exist at local, national, EU and UN 
level, commonalities also become more visible, together with the wish to learn from the 
experiences of others. Another important point addressed is that civil society plays an 
increasingly important role and should be given appropriate attention. In conclusion, 
policymakers call for timely, solution-oriented information and methods which allow them 
to better understand the impact of drug policies. 
The implications for the EMCDDA point towards a need to further develop reporting 
practices on policies, making them more timely, topical, and in formats which are better 
suited to inform policy processes. There is a need to move from the mere description of 
drug policies to the development of tools and methods for policy analysis and evaluation, 
which also need to include instruments for comparative analysis of drug policies, including 
legislation, demand and supply reduction issues. The EU action plan on drugs and the 
evaluation of national drug strategies will be in focus on EMCDDA work. However, local, 
national, EU and international reporting systems are interdependent, and coordination 
between them should be promoted as to be able to transpose and link findings from one 
level to another.
The interventions on practices during the conference emphasised that, in many areas, 
research and systematic evaluations have made it possible to better understand ‘what 
works’. Increasingly, a commitment to evidence-based practice is voiced from both policy 
and practice. However, in reality this commitment is confronted with difficulties in 
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transferring knowledge into actions, due to political sensitivities, old traditions, lacking 
infrastructures and budgetary constraints. Treatment is a much more researched area than, 
for example, prevention, where the majority of interventions are still not evidence-based. 
Sometimes a lack of clarity about the objectives of interventions may lead to different 
definitions of ‘successful outcomes’ or what ‘scientific evidence’ is. There is a need to 
avoid duplication of efforts and to fill the gaps by setting priorities to make best use of 
international and national research investments. Communication is key to promote the 
implementation of evidence-based practice, and it is necessary to bring together different 
types of knowledge, be sensitive to national contexts, and involve stakeholders, including 
service users.
The practices parallel sessions went into detail and highlighted specific aspects related 
to best practice in prevention, treatment and harm reduction, as well as supply reduction 
and interventions in the criminal justice system. Speakers made clear that all interventions 
must be sensitive to the needs of their target groups, and that they must match responses to 
the particularities of different settings and values of the social systems. New patterns of 
drug use and new target groups, e.g. polydrug and non-opiate users, need novel 
approaches, for example, Internet-based treatment. Isolated prevention interventions are 
generally inefficient but community-based, multi-dimensional strategies appear to be more 
successful. Similarly, treatment is increasingly seen as a ‘journey’, with changing objectives 
over the recovery process. In the area of supply reduction, to which the EMCDDA is 
paying increasing attention, data sources are often poorly developed, and there is often 
limited knowledge of what works. A growing awareness of the need for more research in 
this area exists, and the conference highlighted the need for better data from the law 
enforcement field, but also the application of readily available evidence, in particular in 
the prison setting.
The EMCDDA needs to strengthen its role as a platform for knowledge exchange on 
practice. This may be achieved by making better use of the existing expert networks, 
expanding EMCDDA contacts to new areas, developing the best practice portal to 
encompass new areas of responses, and by supporting the development of EU guidelines 
based on national and international experiences, as foreseen in the EU action plan. 
Beyond this, many innovative approaches are interesting — they need to be identified, 
critically evaluated and results reported back to practitioners and policymakers. Supply 
reduction and criminal justice are areas where our experience is limited and where 
conceptual frameworks and tools for data collection need to be developed. 
In summary, with regard to policies and practices, the EMCDDA has a unique position to 
inform policymaking and support the development of drug-related interventions in Europe 
by providing easily accessible and unbiased information. As a platform for knowledge 
exchange, the EMCDDA needs to be aware of the challenges policymakers and 
practitioners face and produce ready-to-use knowledge, tailored to the needs of our 
different audiences. It is also necessary to cover those areas which have as yet received 
only limited attention.
The trends aspects of the conference highlighted multi-method approaches, sensitivity to 
change and timeliness as common issues for efficient drug monitoring systems. Europe can 
learn about the strengths and weaknesses of the EU system by also looking at the US and 
Australia, for example, for issues in relation to monitoring the drug market. One of the 
critical aspects in data collection and analysis, as well as in credibility, is the existence of 
sustainable structures. The European data the EMCDDA collects come from a unique 
structure of national focal points and it is of paramount importance that this system 
receives the attention it deserves. The EMCDDA needs to look further into how to combine 
different types of information (qualitative and quantitative). It will be a challenge to meet 
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the needs for different levels of analysis (local, national and international) and to further 
inquire into the motives for certain behaviours and not simply question whether behaviours 
exist or not.
The trends parallel sessions illustrated that drugs monitoring is almost like hitting a 
moving target: there are new drugs and new users; blurred lines exist between medicinal 
products, legal products and illicit substances; supply routes change constantly. The Spice 
example may be taken as a case study of the challenges we face. However, an increasing 
potential to detect changes and follow them over time now exists, as can be seen, for 
example, in the ESPAD study. An in-depth understanding is needed both of the problems 
and of their consequences. It would be important, for example, to differentiate between 
patterns of use in different user groups and to better understand the problems emerging 
from these. We have learned that we cannot look at single substances from just one 
perspective. Instead we need to look at the complexity of the various (?) phenomena 
involved. New data sources and new analytical approaches, such as modelling, were also 
addressed, as well as interesting novel ideas on how to look at the drugs problem and 
how to analyse it better. The presentations also showed that there is an understanding of 
supply-related issues such as drug market and production, trafficking, and availability. 
Europe is now a major drug producer, the cannabis market has changed radically and 
amphetamine-type stimulants are rapidly spreading in some countries. A holistic approach 
is necessary to understand a dynamic marketplace where old drugs may prove to be new 
threats. Monitoring in this area has considerable potential to inform our understanding but 
the availability, comparability and reliability of data still pose problems and this clearly 
requires further development.
The implications for the EMCDDA’s reporting on trends include the need to maximise the 
analytical value of the available information, for example, by using new and more varied 
sources and approaches to improve sensitivity to new trends, and by developing capacity 
to respond more rapidly to critical information needs. This also highlights the need to 
develop further our approach to monitoring and analysing patterns of use and 
consequences (problems, dependence, morbidity, mortality) and develop and strengthen 
drug market indicators.
The horizons aspects of the conference sketched out new developments in the drugs field 
which already influence this ever-changing area. Neurobiological research explores the 
origins of addiction and adds to the understanding about how it can be prevented and 
treated. New media and new technologies widen the scope of monitoring, both as objects 
for study and as instruments, and the EMCDDA needs to keep track of this rapidly 
developing sector. Drug-related research needs to expand and become better organised in 
order to meet these challenges. Finally, the drugs problem does not stop at the borders of 
the EU and Europe needs to be aware of developments, in particular in its immediate 
vicinity, in order to react in a timely and adequate way. 
The EMCDDA needs, for example, to keep track of advances in technology and provide 
overviews of these developments. It also needs to adjust the monitoring tools to keep them 
on target. The interaction and cooperation with the European research community needs 
to be improved, as data providers and users, and as disseminators. Specifically, we need 
to deal with language issues in order to overcome the current Anglo-Saxon publishing 
bias. Monitoring should be extended to drug use in neighbouring countries by knowledge 
transfer and capacity building. This will help put Europe’s drug situation in context.
In conclusion, this conference has covered a diverse and complex set of themes and 
showed the considerable variety of resources that exist in the EU. Monitoring issues were 
often rather implicit than explicit in our discussions, and it became evident that monitoring 
is an ongoing endeavour with its specific strengths and weaknesses, which produces useful 
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and relevant outputs. Important synergies were clear between the conference debate and 
the EU drug action plan, which is a clear indicator of how the policy agenda has taken the 
key issues on board. Challenges include the difficulty to sustain the existing system during 
a time of financial difficulties and how to constantly improve the sensitivity to change 
whilst remaining non-alarmist and reliable. This conference proved an exciting occasion 
which brought together many key players of not only the European, but also the 
international drugs field. As such, a similar event should be organised by the EMCDDA in 
due course.
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Raising the bar: meeting Europe’s future challenges
Michael Farrell, Chair, EMCDDA Scientific Committee
Many themes have come up recurrently during the conference and overall there is a 
striking positive note and enthusiasm to face up to and tackle future challenges in order to 
improve our response to drug problems. This summary addresses the scientific community’s 
point of view on some of the key issues and challenges that have been raised.
One of the priorities mentioned during this conference is the need to improve access to a 
broad range of scientific knowledge and published data across the European Union, 
taking account of linguistic and cultural aspects, while using new technologies. A key 
challenge is to improve the communication and cooperation across the full range of 
scientific areas involved in drug-related research and to ensure good understanding of the 
links between basic and applied research. There is a major emphasis in many Member 
States on the importance of translational research, and the need to see new developments 
and discoveries in basic science applied to actual practice. This is a big challenge for the 
coming decade. 
The EMCDDA has an important role to play in bringing together the addiction sciences 
and in enabling better links across disciplines on subjects of policy and practice that 
would benefit from a multidisciplinary approach to problem solving. Many of the questions 
in the drugs field will benefit from different disciplines working creatively together to find 
new solutions to old problems. The EMCDDA also has a role in emphasising the 
importance of scientific research in the field of addiction and the need for a broad range 
of scientists to engage with addiction problems. 
Because of the complex nature of drug problems and some of the strong beliefs behind 
tackling such problems, the drugs area benefits from a balanced, well informed empirical 
assessment of approaches that attempts to disentangle what the real benefits of different 
options are and that guides the field to consensus on some of the more controversial 
aspects through robust empirical evaluation. 
Overall, the development of an evidence-based approach to policy and treatment is very 
welcome. In particular there is a need to see that, when good evidence accumulates on 
the benefits of a particular approach to treatment, such an approach is also put into 
practice. However, it is clear that not all problems, conflicts and different views on 
approaches to tackling problems in a field as complex as drugs will be solved simply by 
analyses of the existing evidence and that much uncertainty exists on many important 
questions. In particular, new technologies and new drugs pose potential ethical and policy 
questions that require a measured assessment.
As regards prevention, to date we have relied too much on intervention studies conducted 
in the US and there is a need to have a better range of evidence derived from European 
research and practice. Larger scale European monitoring and evaluation projects could 
help this. A better understanding of the development of individuals, families and 
communities and their resilience in the face of adversity would be very valuable. 
At this 15-year juncture we also note the major achievements of the EMCDDA and the 
success in building up a common framework of information collection. We observe the 
interesting way in which responses to drug problems in Europe have converged 
significantly, despite considerable cultural, social and policy differences. Much of this can 
be attributed to the success of information sharing and exchange of best practices and 
experience. There is still much work for the EMCDDA to do. Ideally, future work would 
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enable us to make better creative use of variations in policy implementation in countries, 
with a firmer view on the policy impact of different approaches. This approach would be 
important when assisting policymakers to obtain better knowledge on the value of different 
approaches. 
The future requires us to continue to build a good knowledge framework that is sustainable 
and that assists in the finding of positive and constructive approaches to tackling Europe’s 
drug problems. The EMCDDA has a key role at the heart of this Europe-wide endeavour 
over the next fifteen years.
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Conference programme 
Opening session 
Chair and introductory address: Wolfgang Götz, EMCDDA Director, Lisbon, Portugal
Opening addresses:
Marcel Reimen, Chairman of the EMCDDA Management Board, Lisbon, Portugal
Francisco Fonseca Morillo, Director at the Directorate-General for Justice, Freedom and 
Security, European Commission
Kamil Kalina, Chairman of the Working Party on Drugs of the Council of the European 
Union
José Sócrates, Prime Minister of Portugal
Conference overview
Wolfgang Götz, EMCDDA Director, Lisbon, Portugal
Plenary thematic session I: Policy
Information needs for policy — implications for 
monitoring and science
Chair: Ingo Michels, Office of the Drug Commissioner of the Federal Government, Berlin, 
Germany
Rapporteur: Frank Zobel, EMCDDA
Presentations
1. Making connections — the questions we have to answer: This presentation will discuss 
how monitoring agencies and researchers can best respond to the needs of policymakers. 
Speaker: Jürgen Rehm, Technical University Dresden, Dresden, Germany
2. The national perspective: Presentation of policy-related information needs at national 
level by a speaker from an EU Member State currently evaluating and reviewing its drug 
action plan.
Speaker: Piotr Jabłoński, National Bureau for Drug Prevention, Warsaw, Poland and 
Pompidou Group of the Council of Europe 
3. The European perspective: Presentation of policy-related information needs at EU level, 
updating and charting the implications of the new action plan for information collection 
and policy formulation in Europe.
Speaker: Carel Edwards, Head of Unit at the Directorate-General for Justice, Freedom and 
Security, European Commission, Brussels, Belgium
4. The international perspective: Presentation of policy-related information needs at 
international level in relation to the UNGASS review. The focus will be on connecting 
reporting at the global level to activities at European and national level.
Speaker: Sandeep Chawla, United Nations Office on Drugs and Crime (UNODC) 
Wednesday 6 May 2009
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5. Civil society forum on drugs: Presentation of policy-related information which can be 
provided by civil society and in particular non-governmental organisations. The focus will 
be on experiences from the ‘Beyond 2008 NGO forums’ held in the framework of the 
UNGASS review.
Speaker: Michel Perron, Canadian Centre on Substance Abuse, Ottawa, Canada
Plenary thematic session II: Practice 
Making the link between science and practice
Chair: Henri Bergeron, Centre of Sociology of Organisations, (CSO), CNRS, Paris, France
Rapporteur: Dagmar Hedrich, EMCDDA
1. Making science speak to policy and practice: An introduction to the difficulties that exist 
on the road from scientific evidence to practice outlining current developments, challenges 
and opportunities.
Speaker: Michael Farrell, Chair of the Scientific Committee of the EMCDDA and National 
Addiction Centre, Kings College, London, UK
2. Understanding the evidence base: The need to critically examine all of the studies and 
evidence on drug-related interventions as collected and analysed by the Cochrane 
Collaboration.
Speaker: Marina Davoli, Italian National Health Service, Department of Epidemiology, 
Rome, Italy
3. Moving beyond experimentation — translating evidence into practice: How to integrate 
findings from randomised controlled trials (RCT) with other types of evidence to further 
develop best practice in a range of interventions and settings.
Speaker: Henk Garretsen, Tilburg University, Tilburg, The Netherlands
4. Doing it well: A review of different best practice scenarios in prevention and treatment, 
looking at target groups, settings, methodologies and evaluation. 
Speaker: Zili Sloboda, University of Akron, Akron, USA
Parallel sessions
Presentations will be structured around the central questions: 
•	What	do	we	know	about	‘what	works’?
•	In	which	intervention	areas	has	progress	been	made	recently	and	how	can	practice	be	
further developed?
•	How	can	we	keep	up-to-date	with	progress	in	intervention	practice	applied	in	real	world	
settings?
A. Treatment and harm reduction, needs for more tailored interventions
Chair: Annette Verster, World Health Organization (WHO)
Rapporteur: Linda Montanari, EMCDDA 
Topics:
1. Making treatment centres more recovery-oriented
Speaker: John Marsden, National Addiction Centre, London, UK
Thursday 7 May 2009
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2. Heroin prescription — new responses for the hard to treat
Speaker: Christian Haasen, University of Hamburg, Hamburg, Germany
3. Addressing psychosocial needs
Speaker: Marta Torrens, Municipal Institute of Medical Investigation (IMIM), Hospital del 
Mar, Barcelona, Spain
4. Meeting different needs — treatment targeted at specific groups 
Speaker: Gabriele Fischer, Medical University, Vienna, Austria
B. From prevention to treatment — finding the right setting for the right group
Chair: Irmgard Eisenbach-Stangl, European Centre for Social Welfare Policy and 
Research, Vienna, Austria 
Rapporteur: Gregor Burkhart, EMCDDA
Topics: 
1. Indicated prevention — targeting those most at risk
Speaker: Gregor Burkhart, EMCDDA, on behalf of Jörg Fegert, Ulm University Hospital, 
Ulm, Germany
2. Prevention in nightlife settings — intervening early by staying up late
Speaker: Amador Calafat, European Institute of Studies on Prevention (IREFREA), Palma de 
Mallorca, Spain
3. Targeting mental health — working in and with the families
Speaker: Joana Prego, Gabinete de Atendimento à Família, Viana do Castelo, Portugal
4. Internet-based interventions — messages that click
Speaker: Peter Tossmann, Delphi Society for Research, Berlin, Germany
C. Interventions related to criminal justice and drug supply
Chair: Brice De Ruyver, University of Gent, Gent, Belgium
Rapporteur: Brendan Hughes, EMCDDA
Topics:
1. Gaps in the knowledge-base — evidence in the criminal justice system and its 
implementation in practice
Speaker: Krzysztof Krajewski, Jagiellonian University, Cracow, Poland
2. Treatment and harm reduction in prison and continuity of care
Speaker: Caren Weilandt, Scientific Institute of the German Medical Association (WIAD), 
Bonn, Germany
3. Alternatives to imprisonment — scope and evidence
Speaker: Alex Stevens, University of Kent, Canterbury, UK
4. Supply reduction — how to define it and how it could be monitored
Speaker: Paul Turnbull, Institute for Criminal Policy, School of Law, King’s College London, 
UK
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Plenary thematic session III: Trends 
Monitoring a fast-moving, complex phenomenon
Chair: Franz Pietsch, Federal Ministry of Health and Women, Vienna, Austria
Rapporteur: Julian Vicente, EMCDDA
1. The Reitox experience — lessons learned in developing a network of national drugs 
focal points and challenges for the future. The Reitox network provides a unique example 
of a regional data collection system gathering comparable and standardised national 
information on the drugs situation in 30 — shortly to become 35 — countries, building on 
national and supra-national resources and commonly agreed commitments. 
Speakers: Alan Lodwick, Head of UK national focal point (NFP) and Reitox Spokesperson, 
Viktor Mravcik, Head of the Czech Republic NFP
2. What can Europe learn from the US experience of policy-related drugs monitoring? The 
United States have a long tradition of monitoring and research. The presentation will allow 
a reflection on how far US ideas could be adapted and used for European needs.
Speaker: Terry Zobeck, The White House Office of National Drug Control Policy 
(ONDCP), Washington D.C., USA
3. What can Europe learn from the Australian experience of policy-related drugs 
monitoring? Australia is another global player in drug research and can offer ideas and 
experiences to be used in Europe to further develop concepts and approaches.
Speaker: Wayne Hall, University of Queensland, Brisbane, Australia
4. The missing link — how do we include qualitative information in monitoring systems? 
While the bulk of research and monitoring is relying on quantitative information, 
qualitative research often offers valuable insight into new developments. Methodologies 
and results will be discussed here. 
Speaker: Dirk Korf, University of Amsterdam, Amsterdam, The Netherlands
Parallel sessions
Presentations will be structured around the central questions: 
•	Europe’s	drug	problem	has	evolved	—	how	do	we	keep	updated?	
•	How	can	monitoring	systems	remain	policy-relevant	and	sensitive	to	emerging	trends?
•	How	can	we	meet	the	challenges	of	monitoring	a	fast-moving	and	complex	
phenomenon?
A. Understanding the intricacies of Europe
Chair: Marcel De Kort, Member of the EMCDDA Management Board 
Rapporteur: Deborah Olszewski, EMCDDA
Topics:
1. ESPAD — are young Europeans getting more alike?
Speaker: Björn Hibell, Swedish Council for Information on Alcohol and Other 
Drugs (CAN), Stockholm, Sweden
2. Keeping on target — the need for more rapid and policy-relevant reporting
Speaker: Jane Mounteney, Bergen Clinics, Bergen, Norway
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3. Blurred lines — prescription, over-the-counter and in-the-post medicinal products 
Speaker: Tim Pfeiffer-Gerschel, Institute for Therapy Research (IFT), Munich, Germany 
4. New drugs coming our way — what are they and how do we detect them? 
Speaker: Les King, former head of the drugs intelligence unit, Forensic Science Service, 
and member of the Home Office Advisory Council on the Misuse of Drugs (ACMD), 
Basingstoke, UK 
B. Drug problems and consequences 
Chair: João Goulão, National Drugs Coordinator, Ministry of Health, Portugal  
Rapporteur: Lucas Wiessing, EMCDDA
Topics: 
1. HIV and HCV, TB and other drug-related infections — the way forward
Speaker: Mirjam Kretzschmar, Centre for Infectious Disease Control, Bilthoven, The 
Netherlands
2. Monitoring drug-related overdose and mortality in Europe 
Speaker: Éva Keller, Semmelweis University, Budapest, Hungary
3. Problem cannabis use — what is it and how to assess it?
Speaker: François Beck, National Institute for Prevention and Health Education, Saint 
Denis, France 
4. Monitoring drug emergencies — what does it tell us?
Speaker: Paul Dargan, National Health Service Foundation Trust (NHS), Guy’s and St 
Thomas’ Hospital, London, UK
C. Trafficking routes and markets 
Chair: Robert Hauschild, Europol, The Hague, The Netherlands
Rapporteur: Laurent Laniel, EMCDDA
Topics:
1. Mapping the changing European cannabis market place
Speaker: Jean-Michel Costes, French Monitoring Centre on Drugs and Drug Addiction 
(OFDT), Paris, France
2. Impact of drug policy on the drugs market
Speaker: Franz Trautmann, Trimbos Institute, Utrecht, The Netherlands
3. Amphetamines — trends in stimulant production and use in Europe
Speaker: Tomáš Zabranský, Center of Addictology at the Psychiatric Clinic, 1st Medical 
Faculty, Charles University, Prague, Czech Republic 
4. What’s happening to heroin? Methodological challenges in understanding trends in 
heroin production and supply
Speaker: Thomas Pietschmann, United Nations Office on Drugs and Crimes (UNODC), 
Vienna, Austria 
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Plenary thematic session IV: Horizons
Arising issues 
Presentations
Chair: Fernando Rodriguez de Fonseca, Fundación Imabis, Hospital University Carlos 
Haya, Malaga, Spain
Rapporteur: Anna Gyarmathy, EMCDDA
1. Drug use and addiction — new scientific findings: Developments in biomedicine, genetic 
and brain research will make the mechanisms of addiction better understood and 
eventually propose new methods of prevention and treatment. What are the information 
implications in terms of monitoring and policy? 
Speaker: Jean-Pol Tassin, Collège de France, Paris, France
2. Emerging research needs: Highlights from the European Commission study ‘A 
Comparative Analysis of Research in the Field of Illicit Drugs in the EU’, updating the 
current state of European drug-related research and analysing research gaps and needs. 
How can research feed into policy? What are the implications for monitoring?
Speaker: Gerhard Bühringer, Institute for Therapy Research (IFT), Munich and Technical 
University of Dresden, Dresden, Germany
3. Looking out from the EMCDDA — regional systems in a global perspective: The 
widening scope of Europe will make it necessary to understand our neighbours’ drugs 
situation in terms of use, production, and trafficking. How do we achieve a wider vision?
Speaker: Paul Cook, International consultant on drugs and drug addiction, Manchester, UK
4. Monitoring in the technological age: The Internet is a medium for information exchange 
of hitherto unknown dimensions for drug users, producers, traffickers, professionals, 
researchers, and policymakers alike. Similarly, new technological advances mean that drug 
use can be detected with increasing precision by analysing waste water. Which possibilities 
and dangers arise from such new monitoring technologies and what are the pitfalls?
Speaker: John Ramsey, St George’s Hospital Medical School, London, UK 
Wrap-up session: Taking forward the findings
Chair: Ralf Löfstedt, Ministry of Health and Social Affairs, Stockholm, Sweden
1. Learning from the past to plan for the future: How is the drugs situation evolving in 
Europe? How will it look in 15 years from now? Looking at past experience, what can we 
predict will happen and what challenges will we face? What research is needed to help 
develop appropriate policies? 
Speaker: Virginia Berridge, London School of Hygiene and Tropical Medicine, London, UK
2. Wrap-up presentations: What has the EMCDDA learnt? 
Speakers: Paul Griffiths and Roland Simon, EMCDDA
3. Raising the bar — meeting Europe’s future challenges
Speaker: Michael Farrell, Chair of the EMCDDA Scientific Committee, National Addiction 
Centre, King’s College London, London, UK
Friday 8 May 2009
Conference programme 
25
Closing session
Chair and final address: Wolfgang Götz, EMCDDA Director
Closing addresses:
Carel Edwards, Head of Unit at the Directorate-General for Justice, Freedom and Security, 
European Commission
Mariano Simancas, Deputy Director, Europol
Aníbal Cavaco Silva, President of the Portuguese Republic
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Policy — Plenary thematic session I
Information needs for policy — implications for 
monitoring and science
Chair: Ingo Michels, German drug coordinator’s office, Berlin, Germany
Rapporteur: Frank Zobel, EMCDDA
Overview
In 2009, two major international drug policy plans — the EU drugs action plan and the 
new UN political declaration and plan of action — are in the spotlight. Furthermore, almost 
half of the 27 EU Member States are drafting or re-drafting their national drug strategy 
and/or their national drugs action plan. The Policy session took a closer look at current 
and future information needs for drug policymaking.
Presentations
1 Jürgen Rehm Making connections — the questions we have to answer
2 Piotr Jabłoński The national perspective
3 Carel Edwards The European perspective
4 Sandeep Chawla The international perspective
5 Michel Perron Civil society forum on drugs
Summary of presentations
Jürgen Rehm explained that due to the illegal nature of drug use, drug monitoring is 
confronted with specific problems regarding sampling and screening. There is also no 
possibility of triangulation with sales data contrary to what is the case with alcohol and 
tobacco. Another problem is that drug policies cover a wide spectrum of activities, which 
makes it difficult to understand what works and what does not work. An experimenting 
and experimental society could be an option. Temporary solutions, or packages of 
interventions, could be assessed by measuring differences between the places where they 
were implemented and the places where this was not the case. However, responses may 
need to change over time, and policymakers must accept that definitive solutions are 
unlikely. Finally, he mentioned the involvement of civil society as one important condition 
for the success of drug-related responses and policies.
Piotr Jabłoński presented the Polish drug programme and the related monitoring and 
evaluation systems. The monitoring system is based on central institutions as well as on 
provincial and regional experts, while the data used for the evaluation of the national 
programme are collected among 30 central institutions and more than 2 500 communities. 
Despite such efforts, and after two evaluation reports, the effectiveness of the policy is still 
not clear. Particular difficulties exist in the modelling of drug problems and drug policies, 
but the development of log frames or matrixes are considered key steps for the evaluation. 
Improving evaluation methodologies is an additional challenge for the future. A better 
understanding of drug-related public expenditure is also of importance. Finally, it was 
observed that politicians expect clear answers to simple questions. Their needs are often 
ad hoc and their goal is to make decisions and take action. Bridging the gap between the 
needs of politics and the work of experts seems to be essential for progress.
Carel Edwards pointed out that policymakers need a relevant knowledge base, policy 
options and that they want immediate solutions. Research is sometimes too slow and its 
results are sometimes disappointing for policymakers. In addition, decision-making is not 
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only based on science but also on many other elements. Thus, researchers should try to 
better understand these policy processes if they want to make an impact on them.  
The European Commission financed a study A report on global illicit drugs markets  
1998–2007, which indicated that, worldwide, there are no reliable data available to 
suggest that the drugs problem has been contained or reduced. Such an uncomfortable 
truth should not be ignored as it undermines the credibility of drug policy. Evaluation and 
data collection are also not always welcome in the supply reduction field. The EU aims to 
ensure that its policies are increasingly based on available scientific evidence. The new EU 
action plan 2009–12 focuses on the availability and quality of services and has one 
important main goal: to delay the onset of drug use. There is a need for monitoring the 
different objectives of this action plan and for obtaining more data on the availability of 
services and on minimum delivery standards, as well as on supply reduction, crime and 
markets. More collaboration within the European drug research community is needed to 
respond to these tasks.
Sandeep Chawla introduced the United Nations Office on Drugs and Crime (UNODC) 
data collection system on drug production, seizures, prices, and on drug use. Cannabis 
and amphetamine production are almost impossible to measure. A survey on cannabis 
production in Morocco is being discussed, while a global survey — based on a set of 
countries — would need USD 10 million of funding. Seizure data have improved, but are 
overall still weak. Data on drug prices in producer countries are quite good but those in 
retail countries are not. Prevalence data are very poor in many parts of the world. Expert 
perceptions are often used, but their validity is unknown. At the last Commission for 
Narcotic Drugs (CND), a resolution on data collection at international level was adopted, 
and the political declaration re-stated the importance of data to inform drug policy. During 
2009, the UNODC is organising expert meetings leading to the revision of the Annual 
Report Questionnaire (ARQ), for consideration and ratification at the 2010 CND. At the 
UNODC, the next practical steps are to support countries in need of information systems 
and the development of prevalence studies; to implement the new Amphetamine-Type 
Stimulants (ATS) programme (SMART); to promote more collaboration with regional 
systems; to carry out more regional extrapolations to estimate drug use; and to insert a 
reference to all data sources in the next World Drugs Report. 
Michel Perron described the consultation process for the NGO initiative ‘Beyond 2008’, 
which was launched in the framework of the UNGASS review. It involved more than 900 
organisations from around the world and ended with a meeting in Vienna with 300 
participants. Among the requests made by the NGOs was the application of common 
standards to measure and evaluate drug demand and harm reduction interventions. The 
NGOs called for shared responsibility in drug policy as they consider that they are best 
situated to represent those most in need. NGOs are a strategic asset and can provide 
data, insight and expertise for the drug policy debates.
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Practice — Plenary thematic session II
Making the link between science and practice
Chair: Henri Bergeron, Centre of Sociology of Organisations, (CSO), Centre nationale de 
la recherche scientifique (CNRS), Paris, France
Rapporteur: Dagmar Hedrich, EMCDDA
Overview
Europe has seen an increase in the provision, effectiveness and diversification of 
prevention, treatment, harm reduction and social reintegration interventions. Sound 
information is the basis for both targeting different kinds of interventions and evaluating 
their impact. However, making the connection between what is known and what needs to 
be done is not an easy task, given the complex nature of real world settings. The Practice 
session explored how to ensure that the evidence available informs practice and critically 
examined the extent to which current approaches are fit for that purpose.
Presentations
1 Michael Farrell Making science speak to policy and practice
2 Zili Sloboda Doing it well
3 Henk Garretsen  Moving beyond experimentation — translating evidence into 
practice
4 Marina Davoli Understanding the evidence base
Summary of presentations
Michael Farrell addressed the dialogue between science and practice, reminding the 
audience of the influence of political and moral values of the social system, and of service 
providers’ as well as service users’ views and opinions as mediating factors. When 
practice identifies a new need for intervention there may be a lack of evidence, and 
research has to be undertaken. However, it might more often be the case that evidence 
exists, but is not widely known, or that more than one intervention is effective, and choices 
have to be made. With a number of examples, including opioid maintenance as a 
treatment option for heroin dependence, he illustrated that the implementation of research 
findings in practice is typically a gradual and rather slow process. It may take between 
one and three decades after evidence is available until guidelines are produced and the 
message reaches practice. A main challenge for health policy is ‘to see things through’, in 
particular as the ‘life span’ of actions, as seen by politicians, is the period of a legislative 
mandate. He ended his presentation with a recent and very striking example of the delays 
in transfer of research to interventions: knowledge about the highly increased risk of 
drug-related death after release from prison has been available since 1998. Still today, 
this has barely been translated into concrete preventive actions. Making a link between 
science and practice involves an ongoing dialogue within the scientific community, and 
between stakeholders in science, policy and practice; but also a stronger culture of 
developing and implementing guidelines.
Marina Davoli talked about the need to critically examine all existing studies on drug-
related interventions in order to understand the evidence base. Practitioners, policymakers 
and the general public are responsible for making use of research evidence, and this can 
not be replaced either by good intentions or plausible theories. She focused on the role 
and achievements of the Cochrane Collaboration’s Drugs and Alcohol Review Group, 
which has in the ten years of its existence developed into a main contemporary transfer 
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tool for information on effective interventions. As one of 51 review groups within the 
Cochrane Collaboration, this international network of experts conducts, updates and 
disseminates systematic reviews on the effects of health care interventions. The reviews of 
the group identify the relevant questions that have been researched, synthesise the results 
and present the ‘best available evidence’, as well as the interventions that are unlikely to 
be beneficial or are even harmful. While underlining that the evidence base for 
interventions differs considerably between the fields of treatment and prevention, the 
reviews produced by the group enable practitioners to keep up-to-date with the relevant 
evidence and help to recognise further areas where evidence is needed. 
Henk Garretsen stated in his presentation that scientific underpinning of policy and care 
is (still) not common, that methods and interventions in the drugs field are often not 
evidence-based and that a gap exists between research and practice. The translation of 
scientific evidence into practice in the drugs field is a three-way process, involving scientific 
research, professional knowledge, and the preferences and experiences of clients. Further 
actors in the definition of drug policies may be local governments, neighbourhood 
associations, or patients’ groups. While randomized controlled trials (RCTs) and meta-
analyses are important inputs and preferable sources of evidence, new interventions and 
policies are often confronted with a lack of research. Also, experimental studies may not 
always be appropriate for specific settings, so other methods must be found to synthesise 
and combine scientific knowledge with information about policy options and with other 
contextual variables in an objective way. Practice transfer, or the continuous, active and 
regular exchange and communication between producers and users of knowledge, is 
needed to improve science.
Zili Sloboda identified the 1990s as the period when the ‘evidence-base’ movement 
began to influence drug prevention and treatment policy in the US, triggering the 
development of a national agenda to move evidence-based prevention and treatment 
programming into communities. This was backed up by the publication of national 
guidelines and principles for prevention and treatment by the National Institute on Drug 
Abuse (NIDA) in 1997. Examining progress about a decade later, some improvement in 
the proliferation of knowledge can be documented, but there is less certainty about the 
sustainability of such efforts. Translation of evidence has been more successful in the field 
of treatment than in the field of prevention, and in prevention, even today, most 
interventions are still not evidence based. Progress was mainly achieved when funding was 
linked to the delivery of evidence-based interventions. In this regard, the prevention field 
has still to catch up and evaluation studies of ‘real world’ prevention programmes are 
needed.
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Practice — Parallel session A
Treatment and harm reduction, needs for more tailored 
interventions
Chair: Annette Verster, World Health Organization (WHO), Geneva, Switzerland
Rapporteur: Linda Montanari, EMCDDA
Presentations
1 John Marsden Making treatment systems more recovery-oriented
2 Christian Haasen Heroin prescription — new responses for the hard to treat
3 Marta Torrens Addressing psychosocial needs
4 Gabriele Fischer  Meeting different needs — treatment targeted at specific groups
Summary of presentations
John Marsden explained that the debate on drug treatment is often polarised between 
two philosophical approaches: abstinence and substitution. At the same time, treatment 
professionals have to deal with a variety of individual needs, from reduction of drug 
consumption to improvement of health and social problems. It is necessary to find a 
rational and balanced approach, based on the real problems of drug users and on 
effective interventions. There is not a unique treatment for everyone, but every treatment 
should be targeted to a unique person. Experience has shown that drug treatment is a 
long-term process, where people usually go through several treatment episodes before full 
recovery. Even after recovery it is important to maintain contact with the client. In order to 
create a flexible and effective system, the UK has adopted an approach based on four 
tiers of drug treatment: Tier 1 — non-specialist/generic services; Tier 2 — open-access drug 
services; Tier 3 structured community-based treatment, and; Tier 4 — residential treatment. 
A client moves across these different levels (treatment journey) aiming at recovery, which is 
defined as what is considered to be the best condition for that specific individual. 
Christian Haasen said that a large proportion of clients in drug services are chronic 
heroin users who have failed several types of treatment. In the US, the American Bar 
Association started the first experiment of Heroin Assisted Treatment (HAT) in 1972. This 
was followed by other countries, also in Europe. Today, HAT is available in some sites in 
Switzerland, the Netherlands, Germany, Spain, and the United Kingdom. In Denmark HAT 
will be available soon, whereas in Norway and France a debate to introduce it has 
started. Studies have been carried out on the effectiveness of HAT, showing largely 
positive results. However, these studies present several methodological limitations (absence 
of a control group, small sample size, etc.), which should be avoided in future studies. 
Recently, a German HAT model project has been implemented, targeting a population of 
long-time heroin users, and the outcome has been evaluated. Evaluation results show 
positive outcomes in improving the patients’ physical and mental health, decreasing 
criminality and contact with other drug users, and reducing substance use. The results 
suggest that HAT may be an important treatment option for chronic heroin users with 
several previous treatment failures.
Marta Torrens showed in her presentation that the high prevalence of co-occurrence of 
substance use and psychiatric disorders represents an increasingly relevant problem in the 
drugs field. Studies show that 40 % to 60 % of problematic substance users seeking 
treatment have a concurrent psychiatric disorder. A study in Barcelona showed that 
substance users, especially polydrug users, report a substantially higher prevalence of 
co-morbidity compared to the general population. Compared to patients with a single 
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diagnosis, those with psychiatric co-morbidity have more individual and social problems 
and a worse prognosis at treatment entry. Treatment of co-morbid patients is complex, 
because of the involvement of both the drugs and the mental health sectors. Often 
interventions are not integrated between the two areas, which has a negative impact on 
the patients’ condition. It is therefore crucial to detect the occurrence of psychiatric 
co-morbidity among drug service users in order to create integrated responses.
Gabriele Fischer talked about pregnant women using drugs as another pertinent group 
who needs targeted interventions. Since a considerable part of women drug users are in 
reproductive age, pregnancy is a crucial issue to consider in drug treatment, and 
substance use is a crucial issue to consider in pregnancy. Treatment for pregnant women 
targets two persons: the pregnant woman and the unborn child. Many studies focus on 
pharmacological treatment targeting the drug use, while it is also fundamental to consider 
other related problems. For example, a high percentage of women in methadone treatment 
have concurrent psychiatric disorders and are heavy tobacco and alcohol users. In 
pregnancy, this may cause various health problems for the woman and the child. Treatment 
for pregnant women aims at stabilising the women’s medical condition and preparing a 
safe environment for the child. The primary objective is to maintain women in substitution 
treatment, since abstinence is mostly an unrealistic goal. Substitution treatment, especially 
with methadone, has proven to have several advantages; however the medication itself has 
never been officially approved by either the US Food and Drug Administration (FDA) or 
the European Medicines Agency (EMEA) for treatment during pregnancy. Buprenorphine 
has become available as an alternative; however, statistical and methodological difficulties 
limit the conclusiveness of research on this substance. 
Summary of discussions
The main objective for drug treatment is the recovery from drug-related problems. The 
concepts of problem drug use and recovery have changed over time. It is becoming clear 
that problem drug use is a chronic condition, which usually needs several treatment 
episodes and a complex mix of interventions. Furthermore, treatment should be targeting 
specific groups of drug users, assessing their needs and analysing the most effective 
treatment options for each of them. Relevant issues to be considered for monitoring at 
European level concern the following topics: 
•	The	assessment	of	treatment	needs	(size	and	characteristics	of	the	population	in	need	of	
treatment) is fundamental to plan suitable and effective treatment
•	Monitoring	should	consider	the	dynamic	nature	of	drug	treatment,	which	is	often	a	
‘journey’ through a complex mix of programmes and interventions
•	The	population	of	problem	drug	users	includes	various	groups	with	specific	needs
•	Long	time	heroin	users,	co-morbid	patients	and	pregnant	drug	users	are	groups	of	
increasing importance in number and gravity in the drugs field
•	There	is	a	need	to	improve	effective	treatment	options	for	clients	using	substances	other	
than opioids
•	Drug	treatment	should	increasingly	be	integrated	with	interventions	from	other	health	
and social fields (mental health, social and alcohol services, gynaecological, paediatric 
and other medical sectors); monitoring should consider that complexity and create 
synergies with other sectors
•	Outcome	studies	based	on	rigorous	scientific	methodology	should	be	encouraged	and	
target specific populations.
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Practice — Parallel session B
From prevention to treatment — finding the right setting 
for the right group
Chair: Irmgard Eisenbach-Stangl, European Centre for Social Welfare Policy and 
Research, Vienna, Austria
Rapporteur: Gregor Burkhart, EMCDDA
Presentations
1 Jörg Fegert Indicated prevention — targeting those most at risk
2 Amador Calafat  Prevention in nightlife settings — intervening early by staying up late
3 Joana Prego Targeting mental health — working in and with the families
4 Peter Tossman Internet-based interventions — messages that click
Summary of presentations
Jörg Fegert presented the findings, methods and background of the research published in 
the EMCDDA Thematic paper Preventing later substance use disorders in at-risk children 
and adolescents. The study, which combined literature review with a survey among 
government officials in Member States, could only identify very few high quality 
interventions. Major attention needs to be given to a clear definition of indicated 
prevention as a new form of intervention that targets the individual, who participates either 
voluntarily or through referral from parents, teachers, social workers or paediatricians. 
Vulnerability is assessed at the individual level and by expert diagnosis. The individual 
might use substances, but does not fulfil criteria for dependence, or show behavioural 
indicators that are highly correlated with an individual risk of developing problematic 
substance use later in life (such as a psychiatric disorder, school failure, antisocial 
behaviour etc.). Several psychopathological features in children are strong predictors for 
later problem drug use. The dual pathway hypothesis suggests that both externalising 
behaviours, such as conduct problems, aggressive behaviour and delinquency, together 
with sensation seeking and lack of impulse control; and internalising disorders, including 
depressive and anxiety disorders, may be risk factors for substance use problems. 
Indicated prevention interventions are therefore highly individualised and, before being 
implemented on a large scale, they need to be carefully evaluated for effectiveness, safety 
and ethical aspects such as stigmatisation, consent and iatrogenic effects. Common 
standards of programme description, evaluation and implementation, as well as better 
development of intervention protocols (including standardised manuals), with large-scale 
evaluations and replications are needed, instead of small-scale ad hoc reinventions at 
local level.
Amador Calafat described and presented a critical analysis of the wide range of 
responses in night-life settings and their capacity to reduce the harm associated with 
recreational drug use. Most uni-dimensional or one-setting interventions do not show clear 
evidence. These include interventions such as Responsible Beverage Serving (RBS); 
alternative leisure activities at the same times and similar venues as conventional events; 
community mobilisation (such as putting pressure on bars); or interventions focusing on 
venues (such as Safe Dancing guidelines). There is also no evidence for the effectiveness 
of information strategies, such as leaflet distribution, when implemented in isolation. 
However, multi-dimensional, community-based approaches in combination with community 
mobilisation appear to be effective, but need political support for sustainability. Such 
strategies might however be difficult to transfer to regions of Europe where community 
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involvement is less common. Some studies in the Nordic countries showed positive effects 
of policing and licensing strategies in nightlife settings. Across all studies, a general 
conclusion is that alcohol use has to be tackled first, since most harm and problems in 
nightlife settings (risky sexual behaviour, violence, intoxication) can be attributed to 
alcohol. 
Joana Prego reviewed the evidence of selective family-based prevention, including the 
development of resilience, on positive family and child development. Prevention 
programmes involving sessions with family, parents and children sessions are much more 
efficient than single-targeted prevention interventions. Programmes should focus on family-
level characteristics, such as communication, cohesion, bonding, joint problem-solving and 
conflict resolution, emotional climate, positive discipline, monitoring and supervision, roles 
and family rules, as well as other family resilience processes such as a positive outlook on 
life, perception of family strength, optimism, positive humour, etc. Evidence-based 
programmes tend to be comprehensive and multi-component, and address family strengths 
and resilience processes, seek to improve relationships and empower families. They have a 
duration of 25 to 50 hours, are appropriate for the age and development of the children, 
and address life cycle transitions. Successful programmes tend to be culturally sensitive to 
the population they serve, incorporate recruitment and retention enhancement strategies, 
have well trained and supervised staff, and use interactive, attractive and diverse 
methodologies. Effective retention strategies for vulnerable families are appropriate 
scheduling (e.g. at the end of the working day), provision of meals and transportation, 
rewards and small gifts for children, or free services, such as babysitting.
Peter Tossman presented the results from the recently launched EMCDDA study Internet-
based drug treatment interventions. A large number of websites provide information on 
drugs, but there are only a few sites that provide interactive counselling, e.g. through chat 
rooms or fora. Only four structured Internet-based treatment protocols could be identified 
in the study, all of them focusing on cannabis users: Know Cannabis (UK), Jellinek Live 
Onlinebehandeling Cannabis (NL), Cannabis onder Controle (NL) and Quit the Shit (DE). 
Most of them share common features such as craving and smoking diaries, tailored 
feedback, a forum, and treatment and emergency plans. Duration ranges from four weeks 
to three months. Three of the programmes are free of charge and anonymous. The 
evaluation of Quit the Shit showed significant positive outcomes on days and amounts of 
cannabis used. 
Summary of discussions
Common to all presentations was the argument that the structure of interventions is key for 
success, i.e. evidence of efficacy for interventions in all areas discussed (indicated 
prevention, prevention in recreational settings, selective family-based prevention, and 
Internet-based treatment) is available only for protocol-based interventions with 
standardised manuals and multiple sessions, and with a sound theoretical base. All four 
experts recommended that best practice examples and standards, as well as screening 
and assessment instruments, should be made available to intervention decision-makers and 
planners, and to practitioners across Member States, in order to increase transfer and 
quality of interventions. Both for family-based prevention and for indicated prevention, 
several important intervention models and assessment instruments are available in non-
drug-related fields of expertise and cross-disciplinary work needs to be encouraged.
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Practice — Parallel session C
Interventions related to criminal justice and drug 
supply
Chair: Brice De Ruyver, University of Ghent, Ghent, Belgium
Rapporteur: Brendan Hughes, EMCDDA
Presentations
1 Krzysztof Krajewski  Gaps in the knowledge base — evidence in the criminal justice 
system and its implementation in practice
2 Caren Weilandt Treatment and harm reduction in prison and continuity of care
3 Alex Stevens Alternatives to imprisonment — scope and evidence
4 Paul Turnbull What is supply reduction and how could it be monitored?
Summary of presentations
Krzysztof Krajewski illustrated that there was little knowledge about the relationship 
between laws and their enforcement. Figures on drug law offences (DLO) generally show 
that law enforcement seems to concentrate on users, but there are big differences between 
numbers of DLOs and convictions. The conviction rate of use-related offences seems to be 
lower than for supply-related offences. It is crucial to study the selection mechanisms, such 
as systems of discretion whether or not to prosecute offenders, and diversions to treatment. 
Gaps in the knowledge about criminal justice interventions are quite substantial. Although 
the criminal justice system identifies users through law enforcement, it is not known if it 
deals with them efficiently or effectively. Collection and analysis of DLO and conviction 
statistics, and relations between them, may contribute to evaluate the effect of law 
enforcement on drug problems, but qualitative research may also be required to answer 
specific questions.
Alex Stevens illustrated how prisons do not deter, rehabilitate, or incapacitate offenders 
nor deliver retribution yet have a high cost. Alternatives to prison (ATPs) have shown to be 
cost-effective ways of reducing both drug use and related crime, and the evidence from a 
study of over 800 offenders in six EU countries is that court-ordered treatment is as 
successful as voluntary treatment for these two aims. Unfortunately, we have no data on 
how many persons enter ATPs in Europe; consequently we also do not know enough about 
the completion rates or of evaluation results at a larger scale. There is evidence that in 
some cases they are: real alternatives to prison but in other cases used in addition to 
prison sentences; the option is used but there is no decrease in the overall imprisonment 
rate. In order to evaluate the impact of ATPs, more facts are needed (numbers, results, 
effectiveness) and understanding of how better targeting may improve success rates. 
Effective treatment guidelines for offenders in the criminal justice system could be added to 
the EMCDDA’s Best Practice Portal.
Caren Weilandt described how increasing drug consumption and drug injecting in prisons 
demand intensified support services. These need to meet the particular requirements for 
security and good order in such settings. (Mandatory) drug testing can have adverse 
effects which could even make it counterproductive. There is a need for more research as 
to the effectiveness of responses in prisons, but the implementation of those types of 
interventions that have already proven effective should improve: prevention (education, 
counselling, including families), treatment (with a range of different treatment modalities), 
harm reduction (screening, vaccination and treatment for infectious diseases, needle and 
syringe exchange programmes (NSP), distribution of condoms, preparation of prison 
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release to decrease overdose risks), and reintegration (post-release aftercare). The cost-
benefit of prison-based interventions should be considered, and prison staff should be 
better informed of these benefits in order to win their support. Research on the 
effectiveness of prison-based interventions should be presented to policymakers, as they 
still seem to need persuasion to implement such measures. A draft proposal for a Council 
Recommendation on drugs in prison, that was called for in the Action Plan on Drugs 
2005–08 to be put forward by the Commission, had still not been tabled. 
Paul Turnbull defined supply reduction as interventions aiming at minimising supply, 
increasing prices, and reducing availability to illicit markets. Their main objective is to 
make drug transactions difficult. Current indicators such as drug law offences, seizures, 
and price data are of limited help to monitor supply reduction as they only report 
successes. One needs to first strengthen the design of the indicators (enforcement activity, 
price, availability), then invest in order to obtain better data. So far it seems that trends in 
the situation have few links with responses. An example from the UK market showed that 
there is poor information on domestic cannabis cultivation and no strategic approach to 
related law enforcement. Nevertheless, recently there is more willingness to evaluate 
interventions, and in the future there should be a closer collaboration between law 
enforcement and researchers. In order to have more accurate figures for monitoring and 
evaluation, one needs to refine indicators and add new measurement criteria, and link 
them. To estimate the domestic production of cannabis, and perhaps also amphetamines 
and other synthetic drugs, data sources other than law enforcement seizures, which are 
very unreliable, are needed.
Summary of discussions
Seizures do not have a major impact on the availability of drugs on the market, thus 
changes in availability are not reflected in a change in prices. However, with local price 
data collection before and after a seizure, some monitoring might be possible. It was 
acknowledged that at least in Poland and the UK, user arrest statistics rose to meet police 
targets rather than for scientific monitoring purposes. Concerning the proposal for a 
Council recommendation on prison and drugs, it was clarified that the Commission had 
recently published an overview report on the status quo of drug-related health services in 
prison, on reintegration and on monitoring. Although issues of subsidiarity are still being 
assessed, access to health care for drug users in prison is an objective in the action plan 
on drugs 2009–12. Technical work will focus on the development of a framework for 
monitoring in the prison setting and the EMCDDA will play an important role in this 
respect. Furthermore, three supply reduction indicators are to be developed under the EU 
drugs action plan. It was discussed whether ATPs could encourage people to commit 
crimes in order to get into treatment. However, research had shown that the reasons to 
commit crimes were far more complex, and treatment was certainly not a main incentive. 
At the same time, it is true that offenders may overcrowd the treatment system, sometimes 
to the detriment of more needy voluntary clients. Overall, the main message from the 
presentations was that researchers are not yet able to measure the efficiency and 
effectiveness of Criminal Justice System (CJS) responses. There is a resistance from the CJS 
to give away the data they may have, and the data might not be useful. It would be 
preferable if, in the future, the CJS could collect data for research and not only for 
operational purposes, and that it could share it.
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Trends — Plenary thematic session III
Monitoring a fast-moving, complex phenomenon
Chair: Franz Pietsch, Federal Ministry of Health and Women, Vienna, Austria
Rapporteur: Julián Vicente, EMCDDA
Overview
The European drugs problem today differs considerably from the situation in the early 
1990s when the EMCDDA began its work. The problem of heroin remains, but cocaine, 
cannabis and polydrug use play a different role than they did before. New psychoactive 
substances present an additional challenge, as does the misuse of prescription medicines. 
In addition, drug availability has changed considerably through geopolitical influences 
and changes in production. The Internet has impacted on both the availability of drugs 
and on methods of information collection and dissemination. Europe’s drug monitoring 
capacity has developed considerably but now needs to provide a picture of a faster 
moving and more diverse phenomenon — these are the challenges that the Trends session 
addressed.
Presentations
1 Alan Lodwick and Viktor Mravcik  The Reitox experience — lessons learned in 
developing a network of national focal points and 
challenges for the future
2 Terry Zobeck  What can Europe learn from the US experience of 
policy-related drugs monitoring?
3 Wayne Hall  What can Europe learn from the Australian 
experience of policy-related drugs monitoring?
4 Dirk Korf  The missing link — how do we include qualitative 
information in monitoring systems?
Summary of presentations
Alan Lodwick and Viktor Mravcik outlined how fifteen years ago the European Union 
put in place a monitoring centre, the EMCDDA, and a system for collecting and reporting 
drug information, the Reitox network of national focal points (NFPs). Over the years the 
network has developed and implemented common methodologies and conceptual 
frameworks with a range of harmonised instruments for data reporting. The tasks of NFPs 
include the collection of epidemiological data, policy and demand reduction information, 
including examples of best practice, supply and market data, and early warning 
information. A reporting package consisting of national reports, standard tables and 
standard questionnaires is submitted annually. The administrative structures of the NFPs are 
diverse and depend on national decisions. But from a practical point of view, all NFPs 
have a key role as national reference points on drugs. With the progressive expansion of 
European drugs monitoring to 27 Member States and several associated countries, the 
considerable differences in social and cultural contexts and in their evolution, the various 
forms of organisation of social and health services and policies, and the diverse nature of 
markets and drug availability must be taken into account. In order to function effectively, it 
is necessary to strike a balance between standardisation and flexibility, in order to adapt 
reporting to new developments in drug use, consequences and responses.
Terry Zobeck presented the drugs monitoring strategy of the Office for Drug Control 
Policy (ODCP) in the United States. It includes four domains: prevalence of drug use, drug 
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availability, consequences of drug use and drug availability, and the status of drug 
treatment. Each domain is represented by a set of specific indicators and data sources 
used. Estimates are generated annually to enable monitoring of changes in critical, policy-
relevant indicators, for example prevalence data from population surveys and selected 
groups (i.e. arrestees), estimated treatment needs, reported drug-induced deaths, 
estimated economic cost of the national drug policy, and different indicators of drug 
availability and supply. A harmonisation between US and European measures would 
facilitate the ability to address international drug markets.
Wayne Hall presented the Australian drugs monitoring system. This system is based on 
classical population surveys, mortality (overdoses) and morbidity (hospital discharges and 
treatment demand) data, as well as a new component to track drug use, consumption 
patterns and drug availability: this uses sentinel populations (arrestees, panels of injecting 
and recreational users) together with professionals as key informants. This innovative 
component was presented in detail, regarding methodology, e.g. sampling criteria, its 
strengths and limitations, and results. In meetings, researchers analyse observations on 
phenomena such as overdose deaths and emergency calls, effects on treatment services 
and crime, the availability of substances, stimulant use and related harms, as reflected by 
the evidence from the panels.
Dirk Korf focused on the added value of qualitative information to give insight and 
understanding to results obtained by classical quantitative monitoring methods. Qualitative 
methods can be essential to interpret epidemiological indicators, for example, why people 
use or do not use drugs, how they use them, under which circumstances, how they perceive 
benefits and risks. The strengths of such methods lie in a better understanding of 
behaviours, beliefs and attitudes related to drug use, whereas there are limitations in 
completeness and comparability. Qualitative research methodologies such as ethnography 
and panel studies, and theoretical concepts (i.e. triangulation, contextualisation) were 
exemplified in case studies on the geographical and social diffusion of different forms of 
drug use.
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Trends — Parallel session A
Understanding the intricacies of Europe
Chair: Franz Trautmann, Trimbos Institute, Utrecht, the Netherlands
Rapporteur: Deborah Olszewski, EMCDDA
Presentations
1 Björn Hibell ESPAD — are young Europeans getting more alike?
2 Jane Mounteney  Keeping on target — the need for more rapid and policy relevant 
reporting
3 Tim Pfeiffer-Gerschel  Blurred lines — prescription, over-the-counter and in-the-post 
medicinal products
4 Les King  New drugs coming our way — what are they and how do we 
detect them?
Summary of presentations
Björn Hibell presented ESPAD, a multinational survey among 15- to 16-year-old school 
students. An increasing trend was found in cannabis use from 1995 to 1999 to 2003 but 
this trend was broken with lower figures in 2007 (based on 20 countries with data from all 
four surveys). Increases in illicit drug use from 1995 to 2007 were mainly found in new 
EU Member States in central and eastern Europe. Proportions that have used cannabis 
were higher in 2007 than in 1995 but European students were not much more alike in 
2007 than they were in 1995. The differences between high and low cannabis prevalence 
countries remained about the same. However, there were increases in some countries in 
eastern Europe while there was a decrease in some western European countries. Girls’ 
pattern of use has become more like boys’ regarding cigarettes and alcohol, but there was 
no change regarding illegal drugs.
Jane Mounteney suggested that the best solution to speed up drugs monitoring is to use 
city level and/or local systems to avoid bureaucratic delays. Pragmatic and 
unconventional use of existing data, and multi-indicator and multi-method approaches may 
be more advantageous than launching new studies. The validity of studies can be attained 
through triangulation of sources, methods and results. Researchers may include sensitive 
sources (key informants and media), or rapid assessment and response methodology. Early 
identification and speedy reporting of new developments allow for early intervention. 
Policymakers need to be involved when choosing the focus of investigation and integrated 
action is necessary in planning research that offers solutions.
Tim Pfeiffer-Gerschel defined the topic of his presentation as the ‘non-medical use of a 
prescription drug without a doctors prescription (encompassing self-medication and 
recreational use)’. The situation in Europe is blurred. Different user groups (age, gender, 
background) are involved and they are difficult to identify and distinguish. Among these 
subtypes are adolescents utilising such drugs for recreational or experimental purposes; 
users of other psychoactive substances including alcohol, nicotine, other prescription 
drugs, and all kinds of illicit drugs; chronic pain patients; and elderly people. Information 
is partly available for drug treatment clients but specialised treatment centres only reach 
parts of the total using population, and ‘hidden’ populations are difficult to access. The 
question arises which additional groups should be monitored, how and to what extent. 
ICD-10 codes (International Classification of Disease) are insufficient for monitoring this 
type of drug use. Frequently, misuse of pharmaceuticals remains undiscovered and is often 
regarded as less problematic than other substance use problems. 
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Les King put forward that most of the 90 new psychoactive substances that have been 
reported in the last years are synthetic compounds. Most were not widespread and most 
did not survive for long on the illicit market. Nearly all of these substances presented 
analytical challenges when first encountered, and for many, little was and still is known 
about their pharmacology and toxicology. Nearly all substances had been described in 
the scientific literature, they are effectively ‘failed’ pharmaceutical agents. In the early 
years of ‘new drugs’ monitoring, most substances were either phenethylamines or 
tryptamine derivatives. Since then a much more diverse range of substances has 
appeared, including piperazine derivatives, one of which, 1-benzylpiperazine (BZP), was 
risk-assessed in 2007 and recommended for EU-wide control. Rather than being reactive, 
it should be possible to anticipate new substances given a knowledge of the literature and 
the use of a set of rules for predictions. The emergence of products such as Spice, which 
serves as a ‘Trojan Horse’ for synthetic cannabinoids, highlight the legal, analytical and 
toxicological problems faced.
Summary of discussion
The discussion highlighted some key gaps in information and understanding. One 
suggestion was that solutions may be found by reference to historical data, particularly in 
the field of alcohol and tobacco. Better use could be made of the differences within the 
EU to gather evidence and improve understanding, using both quantitative and qualitative 
methods.
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Trends — Parallel session B
Drug problems and consequences
Chair: João Goulão, National Drugs Coordinator and Director of the Instituto de Drogas 
e Toxicodependências (IDT), Lisbon, Portugal
Rapporteur: Lucas Wiessing, EMCDDA
Presentations
1 Mirjam Kretzschmar  HIV and HCV, TB and other drug-related infections — the way 
forward
2 Éva Keller Monitoring drug-related overdose and mortality in Europe
3 François Beck Problem cannabis use — what is it and how to assess it?
4 Paul Dargan Monitoring drug emergencies — what does it tell us?
Summary of presentations
Mirjam Kretzschmar showed how infectious diseases display a dynamic behaviour over 
time and that differences between countries in infection prevalence of HIV, HCV and HBV 
in IDUs (injecting drug users) are substantial. Together with the EMCDDA she is 
coordinating a network of mathematical modellers and epidemiologists who try to increase 
the understanding of the epidemiology of these drug-related infections. There are 
important associations between HIV and HCV, where HCV prevalence may be used as an 
indicator of injecting risk behaviour and of the risk of HIV outbreaks in counties where HIV 
in IDUs is still low. She presented the modelling work that is being performed to estimate 
the force of infection and incidence from cross-sectional prevalence data, and how the 
heterogeneity in force of infection between different infections in a population of IDUs may 
provide another indicator of risk behaviour. Although there is little doubt that harm 
reduction interventions reduce self-reported risk behaviours, there is still a discussion as to 
whether the evidence for their effectiveness for preventing HIV, and especially hepatitis 
infections, is conclusive or not. More work is needed to disentangle the effects of harm 
reduction from other effects such as demographic changes. There is a need for 
strengthening the European research area by creating conditions for more comparable 
epidemiological data collection (surveys, cohort studies) in Member States. This should 
enhance the potential to apply mathematical and statistical modelling and other analytical 
tools to assist public health and drug policies by increasing the understanding of the 
epidemiology of infectious diseases in IDU.
Éva Keller discussed the two major types of drug-related deaths: those that are directly 
caused by drug consumption (e.g. overdose) and those that are indirectly related, such as 
resulting from AIDS, accidents, suicide, or violence. A range of factors determine the final 
coding of a drug-related death, and differences may be due to the legal system, the 
examination to determine the cause of death, scene investigation, autopsy, the national 
data collection system, toxicology in emergency rooms or hospitals, and the coding of the 
results. In Hungary, a new monitoring system has been set up, and the data quality and 
reliability on drug-induced deaths have improved. The Hungarian methods were compared 
with other Member States’ drug-related death data collection systems.
François Beck discussed how the high prevalence of cannabis use in the population and 
increasing treatment demand for cannabis use may suggest that problematic use is 
increasing in Europe. General population surveys may not reach all illegal drug users, and 
there is no consensus on what cannabis-related problems are. He defined problematic 
cannabis use as the ‘use leading to negative consequences on a social or health level, 
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both for the individual user and the larger community’. He discussed different screening 
tests for problematic cannabis use. Some criteria for problematic cannabis use, e.g. in 
DSM-IV (Diagnostic and Statistical Manual of Mental Disorders), may be confounded by 
the legal status of the drug, for example ‘spending a great deal of time obtaining the 
substance’ or ‘feeling of guilt after using cannabis’, The French screening test CAST 
consists of six questions such as ‘have you ever smoked cannabis before midday’ or ‘have 
you ever smoked cannabis when you were alone’. Measuring problem or dependent 
cannabis use is complex; however, implementation of a common screening tool can deliver 
important information for prevention in Europe. With an increasing demand for cannabis 
treatment, it is crucial to be able to distinguish those who suffer from a cannabis use 
disorder or who manifest patterns of cannabis use that may require an intervention. There 
is a need to develop screening tests which are more reliable in measuring the adverse 
effects of cannabis use. 
Paul Dargan discussed how and why the monitoring of drug emergencies should be 
implemented at European level. Recreational drug use is common across Europe. Data 
from one hospital in the UK showed that cocaine, MDMA and GHB/GBL were the most 
common drugs associated with hospital presentations with acute toxicity. A major limitation 
of such datasets is that they rely on patients’ self-report of the drug(s) used, since 
toxicological screening is not undertaken routinely. There is a need for adequately funded 
research involving the systematic screening of recreational drug toxicity presentations to 
fully understand the epidemiology of established and novel/emerging recreational drugs, 
and establish patterns of toxicity associated with individual agents. Such research can then 
be used to inform drug legislation and develop guidelines for the management of 
recreational drug toxicity.
Summary of discussions
There appears to be a move away from purely descriptive drugs monitoring towards 
increasing use of advanced research and analysis tools, especially in the more established 
areas such as infectious diseases. Several speakers suggested that there is a need in 
Europe to more strongly support the implementation of research designs and 
epidemiological analysis techniques, such as surveys, cohort studies and mathematical 
modelling, and to take better stock of the available data and expertise in order to provide 
more useful information for policymaking. The importance of social determinants on data 
and data quality was apparent, for example, regarding both drug-related deaths and 
infectious diseases. Stigma and shame often cause under-notification of cases and may 
lead to considerable bias in routine monitoring systems, which should be assessed. The 
session also highlighted the potential for developing new indicators and data sources that 
are more sensitive to tracking trends in acute health problems, such as drug emergencies.
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Trends — Parallel session C
Trafficking routes and markets
Chair: Robert Hauschild, Europol
Rapporteur: Laurent Laniel, EMCDDA
Presentations
1 Jean-Michel Costes Mapping the changing European cannabis market place
2 Franz Trautmann Impact of drug policy on the drugs market
3 Tomáš Zábranský  Amphetamines — trends in stimulant production and use in 
Europe
4 Thomas Pietschmann  What’s happening to heroin? Methodological challenges in 
understanding trends in heroin production and supply
Summary of presentations
Jean-Michel Costes presented an ongoing study by a group of French partners of the 
EMCDDA: the Observatoire français des drogues et des toxicomanies (OFDT), the Institut 
national des hautes études de sécurité (INHES) and the National Forensic Laboratory of 
Lyon. The main objectives of the study are to map major cannabis trafficking routes to and 
within Europe, in particular a shift away from cannabis resin produced in Morocco toward 
European-grown herbal cannabis, mainly from Albania. Cannabis is the main illicit drug 
consumed in Europe, with 13 to 14 million people having used it in the past 30 days. 
Among the early results presented, an estimate of the size of the market suggested that 
between 1 500 and 2 000 metric tonnes of cannabis may be consumed in the EU each 
year, and an insight into the relative efficacy of police and customs agencies in countering 
cannabis trafficking was discussed. 
Franz Trautmann presented key results from A report on global illicit drugs markets, 
1998–2007, a study carried out by the Trimbos Institute and the Rand Corporation and 
financed by the European Commission. Policy trends were described for the 10-year 
period. Drug policy expenditure increased substantially in many countries, with the 
majority of funding going to supply reduction. Measures against production and trafficking 
intensified (more arrests and tougher penalties), as did demand and harm reduction 
measures (consensus on the importance of prevention, in spite of doubts regarding its 
effectiveness). Drug use was stable or declining in western countries; although an increase 
in cocaine use in Europe was noted. Regarding supply, cocaine and heroin were fairly 
constant with production concentrating in Afghanistan for opium and Columbia for coca, 
while the evolution of cannabis and ATS supply was depicted as diffuse, with production 
sites in a wide range of countries. The impact of anti-trafficking measures on quantities 
trafficked was said to be hard to measure. A number of unintended policy consequences 
were highlighted, while the study suggested that control efforts have a minimal effect on 
global drug supply. 
Tomáš Zábranský talked about amphetamine, methamphetamine and other ephedrine-
based substances in Europe. Amphetamine issues have traditionally affected mainly 
countries in north-western Europe (British Isles and Scandinavia), while methamphetamine 
is a highly-prevalent problem drug only in the Czech Republic, and lately Slovakia, where 
it has replaced heroin as the main problem drug. Use and production of 
methamphetamine-related substances has increased substantially worldwide, including — 
although to a lesser extent than in other world regions — eastern EU and neighbouring 
countries. Thus, the use of ephedrine-based drugs, like methamphetamine and 
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methcathinone, seems to be rapidly increasing in prevalence in the Baltic states, Hungary, 
Russia and the Caucasian countries, and there is a new trend of recreational use of such 
substances. The relatively straightforward production of small amounts of ephedrine-based 
substances from a wide array of easily available products, and the rapidity with which use 
may spread are challenges for control, as well as monitoring and early warning systems in 
the EU and beyond. 
Thomas Pietschmann introduced the UNODC’s approach for measuring the area under 
poppy cultivation, opium yields and amounts produced, as well as amounts of morphine 
and heroin manufactured, especially in Afghanistan. After presenting the latest UNODC 
survey results and providing forecasts of trends for 2009, additional UNODC monitoring 
activities in Afghanistan were described, notably price data collection. Estimates of the 
outflow of opium and morphine/heroin from Afghanistan to neighbouring countries, the 
issue of opiates stockpiles, and the main drug trafficking routes to Europe were also 
presented. Finally, areas needing further research to improve understanding of the impact 
on Europe were highlighted.
Summary of discussions
Two interesting points emerged from the discussion. Firstly, there is a need to set up ‘real-
time’ monitoring systems of drug trends in order to detect new trends quicker than is 
presently the case. These could be based on a range of qualitative data (interviews of key 
informants, analysis of seizures, etc.), which were suggested to be better able to identify 
new trends quickly. Quantitative systems often pick up new trends too late for effective 
action, for instance only after a new drug epidemic is well underway. There is also a need 
to improve understanding of the amounts of illicit drugs traded each year on European 
markets. A first step in this direction would be to carry out research into patterns of use 
and the corresponding amounts of drugs consumed by individual users. Better knowledge 
of total amounts consumed would contribute a great deal to understanding the general 
dynamics of drug markets, and would be especially useful to identify major destinations 
for the opiates produced in Afghanistan.
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Horizons — Plenary thematic session IV
Arising issues
Chair: Fernando Rodriguez de Fonseca, Fundación Imabis, Hospital University Carlos 
Haya, Málaga, Spain
Rapporteur: V. Anna Gyarmathy, EMCDDA
Overview
The world of science is constantly evolving, as are patterns of drug use and communication 
structures. New scientific findings deepen our understanding of the mechanisms behind 
drug use and drug addiction. New methodologies make us know more about human 
behaviour and analyse our findings better. The Horizons session highlighted recent 
developments and outlined information needs and perspectives for the future, including 
ethical issues.
Presentations
1 Jean-Pol Tassin Drug use and addiction — new scientific findings
2 Gerhard Bühringer Emerging research needs
3 Paul Cook  Looking out from the EMCDDA — regional systems in a global 
perspective
4 John Ramsey Monitoring in the technological age
Summary of presentations
Jean-Pol Tassin summarised research on the neurobiological processes of pleasure. Much 
research has focused on the role of the ‘addiction hormone’ dopamine, the release of 
which is related to the feeling of pleasure. Cocaine blocks the re-uptake of dopamine, 
hence dependence develops. The NA/5-HT coupling system is related to the dopamine 
system, and this coupling system is destroyed (‘uncoupled’) when drugs are used. Another 
aspect of addiction is the interconnectivity between drugs: if mice are sensitised to 
cocaine, they will also be sensitised to other drugs (e.g. amphetamines, opiates etc.). The 
repeated consumption of drugs results in the uncoupling of the NA/5-HT system, which 
results in hyperactivity and chronic stress. Drugs artificially re-couple the system and bring 
temporary relief.
Gerhard Bühringer pointed out that much of existing drug-related research is published in 
the US. This situation is due to a deficit of research funding and to the complexities of the 
drugs problem in Europe. There is a need for interdisciplinary research and for better 
management of research, especially research outcome analysis, so that published research 
is followed up. Another problem in Europe is the low quality of the research infrastructures: 
there is a lack of qualified research staff and research networks. However, one of the main 
problems is the lack of funding continuity. He ended his presentation by calling: ‘Scientists 
of Europe unite’.
Paul Cook elaborated on the drugs situation east of the European Union, and the drug 
monitoring activities within the EU programmes for countries in the process of accession and 
under the European neighbourhood policy. In order to understand and describe the drug 
situation in each of these countries in terms of use, production and trafficking, the five key 
epidemiological indicators developed in Europe have been implemented. One major 
problem is that the more we travel east from Europe, the more cultural differences we find. 
These cultural differences need to be understood in order to work with these nations. The 
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EMCDDA can assist by delivering comparable and compatible monitoring systems to 
countries which have only just started or which plan to start reporting on the drugs situation.
John Ramsey called attention to the fact that there is a large variety of new drugs and 
they have various alternative forms. Widespread standard methods to detect them are 
indirect modelling, which observes trends in drugs based, for example, on test purchases, 
the use of drugs in biological samples, and impairment tests. Also, new advanced and 
expensive technology can be used. Oral fluid testing can help detect and monitor drug 
use better than urine testing due to its ease of use. Thermal imaging is one method to 
detect indoor cannabis production. It detects buildings that are hotter than surrounding 
buildings, hence potential locations for clandestine greenhouse plant production. This is 
because such production requires a considerable amount of heat and artificial light.
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Taking forward the findings
Chair: Ralf Löfstedt, Swedish Ministry of Health and Social Affairs, Stockholm, Sweden
Presentations from Paul Griffiths and Roland Simon, as well as Michael Farrell included 
earlier in this publication were made at this point in the proceedings to wrap-up the event. 
The following presentation by Virginia Berridge gives valuable insight into how previous 
events and experiences can help guide and inform current and future practice.
Presentation
 Virginia Berridge Learning from the past to plan for the future
Summary
Virginia Berridge informed the delegates that 20 years ago she produced a report called 
Drug Research in Europe, commissioned by WHO’s European Regional Office. She 
travelled through Europe interviewing researchers and policymakers who commissioned 
research. The idea of European cooperation in the drugs field was in its infancy. Networks 
of researchers gathered to argue about the development of common indicators in groups 
such as the ‘multi city study’. This was at the time when the EMCDDA was about to be set 
up. The structures which operate in Europe now are very different. Struggles over data sets 
and data formats are over and information is available in a common format. Convergence 
is the subject of current debate. This could involve adhering to some common features of 
policy, despite enduring national differences. Or it could mean seeking common 
approaches across the substances of drugs, alcohol, tobacco and prescription drugs. To 
understand potential future developments we need to understand that the relationship 
between evidence and policy is complex, often the result of a long process. We will need 
different forms of evidence, moving beyond epidemiology and integrating quantitative and 
qualitative research. An historical understanding of where we have come from and an 
appreciation of policy processes will teach us to look back in order to look forward.
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